Activity Dates: 11/27/2019 - 05/30/2020This recertification course is closed. Check the availability of the latest recertification products.
This self-study activity serves as an educational tool for pharmacists seeking Board Certified Psychiatric Pharmacist (BCPP) Recertification credit and other pharmacists and health care providers seeking advanced education in patient and disease state management in the field of psychiatric pharmacy.
This recertification product consists of four clinical review articles focused on single disorders, or on one or more distinct aspects of a single psychiatric, neurologic, or substance use disorder. Authored by leading experts in the field and hosted in CPNP’s peer-reviewed journal, The Mental Health Clinician (MHC), these case-based articles will be fully referenced and offer therapeutic advice based on both evidence and longstanding clinical experience. Pearls articles focus on aspects of disease states and their pharmacotherapy that require synthesis of solutions to problems or development of practices that require judgement(s) founded on evidence, but modified or tempered by extensive clinical experience and practicalities of “real world” necessities. The articles are intended to allow you to gain greater insights into the strategies of clinical decision-making used by expert clinicians. Topics include PTSD guidelines, opioid use disorder and pregnancy, clozapine augmentation, and multiple sclerosis.
Psychopharmacology Pearls is an application-based continuing pharmacy education (CPE) activity. An application-based CPE activity requires that participants apply the information learned. The examination for this product often features case studies requiring that the participant apply the principles learned through the readings. Psychopharmacology Pearls includes:
To satisfactorily complete the Psychopharmacology Pearls and receive 5 hours of BCPP Recertification and ACPE credit, candidates must meet the following requirements:
You will proceed through the following steps to satisfactorily complete this course:
Participants successfully passing the required assessment/examination will obtain both ACPE and BCPP recertification credit. Credit is awarded in the calendar year the assessment is completed. ACPE credit is reported through CPE Monitor within days of examination submission, while BCPP recertification credit is reported to BPS within 6 weeks after the examination deadline.
CPNP has invested in supporting the most popular web browsers and leveraging software that our members use daily. Beyond PDF downloads, the rest of the system is built on HTML5, a technology that most up-to-date browsers will support. To access CPNP course materials online, you will need:
CPNP web sites no longer fully support Microsoft Internet Explorer 9 and older or Windows 7 and older. We cannot guarantee that the site will function perfectly on every device and configuration, but using the latest version of the software above will greatly improve your experience.
Megan J. Ehret, PharmD, MS, BCPP
Nicole Hahn, PharmD, BCACP
Kristin Harter, PharmD
Shilpa Klocke, PharmD, BCPS
James L. Roerig, PharmD, BCPP
Clozapine Augmentation Strategies
Opioid Use Disorder in Pregnancy
Treatment of Posttraumatic Stress Disorder: Focus on Pharmacotherapy
The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The Psychopharmacology Pearls product is an application-based program approved for 5 ACPE contact hours. To receive ACPE credit, pharmacists completing this programming are required to complete an evaluation of the course as well as pass an online examination.
Board Certified Psychiatric Pharmacists (BCPPs) may also receive 5 hours of BCPP Recertification Credit for the Psychopharmacology Pearls upon successful completion of an online examination.
The articles in this learning activity were developed by the authors in conjunction with the planning committee. Each article subsequently was peer-reviewed and copyedited by the Mental Health Clinician (MHC) prior to publication. As a scholarly journal, the MHC utilizes external double-blind peer review such that reviewer details are not presented here. MHC Editorial Board policies are online.
It is the policy of CPNP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by CPNP for any product or manufacturer identified.